Jackson Creek Investment Advisors LLC Acquires New Holdings in Castle Biosciences, Inc. (NASDAQ:CSTL)

Jackson Creek Investment Advisors LLC purchased a new position in shares of Castle Biosciences, Inc. (NASDAQ:CSTL - Free Report) during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 57,094 shares of the company's stock, valued at approximately $1,143,000. Jackson Creek Investment Advisors LLC owned approximately 0.20% of Castle Biosciences at the end of the most recent reporting period.

Other institutional investors have also recently bought and sold shares of the company. Covestor Ltd bought a new position in Castle Biosciences during the fourth quarter worth about $25,000. CWM LLC raised its holdings in shares of Castle Biosciences by 835.0% in the 1st quarter. CWM LLC now owns 4,142 shares of the company's stock worth $83,000 after buying an additional 3,699 shares in the last quarter. GAMMA Investing LLC raised its holdings in shares of Castle Biosciences by 1,865.8% in the 1st quarter. GAMMA Investing LLC now owns 4,364 shares of the company's stock worth $87,000 after buying an additional 4,142 shares in the last quarter. KLP Kapitalforvaltning AS acquired a new position in shares of Castle Biosciences in the 4th quarter worth approximately $128,000. Finally, Teacher Retirement System of Texas raised its holdings in shares of Castle Biosciences by 9.6% in the 1st quarter. Teacher Retirement System of Texas now owns 10,383 shares of the company's stock worth $208,000 after buying an additional 908 shares in the last quarter. Institutional investors and hedge funds own 92.60% of the company's stock.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on CSTL shares. Canaccord Genuity Group dropped their price objective on shares of Castle Biosciences from $42.00 to $37.00 and set a "buy" rating for the company in a report on Tuesday, May 6th. Guggenheim set a $30.00 price target on Castle Biosciences and gave the company a "buy" rating in a report on Friday, March 28th. Scotiabank dropped their price target on Castle Biosciences from $44.00 to $40.00 and set a "sector outperform" rating for the company in a report on Wednesday, May 21st. Finally, Lake Street Capital dropped their price target on Castle Biosciences from $40.00 to $35.00 and set a "buy" rating for the company in a report on Tuesday, May 6th. Eight analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has an average rating of "Buy" and a consensus target price of $37.00.

Castle Biosciences Trading Up 0.0%

Shares of NASDAQ:CSTL traded up $0.01 during trading on Monday, hitting $16.55. 122,701 shares of the company's stock were exchanged, compared to its average volume of 419,369. Castle Biosciences, Inc. has a 1-year low of $15.45 and a 1-year high of $35.84. The firm has a 50-day moving average price of $18.09 and a two-hundred day moving average price of $21.37. The company has a current ratio of 9.37, a quick ratio of 9.19 and a debt-to-equity ratio of 0.02. The firm has a market cap of $477.65 million, a P/E ratio of -87.08 and a beta of 1.10.

Castle Biosciences (NASDAQ:CSTL - Get Free Report) last issued its quarterly earnings results on Monday, May 5th. The company reported ($0.20) EPS for the quarter, missing the consensus estimate of ($0.08) by ($0.12). Castle Biosciences had a positive return on equity of 3.41% and a negative net margin of 1.46%. The business had revenue of $87.99 million for the quarter, compared to analyst estimates of $80.40 million. Equities analysts predict that Castle Biosciences, Inc. will post 0.44 earnings per share for the current year.

Castle Biosciences Profile

Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.